CJC-1295 + DAC - 2mg

SPECIFICATIONS

Product Code: CJ1D02

Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Malimide-beta-Ala)-NH2

Molecular Formula: C165H269N47O46

Molecular Weight: 3648.4 g/mol

CAS: 863288-34-0

Purity: Technical / Research Grade 98%

Other details: No TFA Salt

Form: Lyophilized powder

Color: White

Storage temperature: -20°C

Source: Synthetic

Safety classification: Standard handling

DESCRIPTION

CJC-1295 is a synthetic peptide derived from the first 29 amino acids of growth hormone–releasing hormone (GHRH) and belongs to a class of GHRH analogues structurally related to other short GHRH mimetics, such as modified GRF (1-29). Although these peptides share sequence similarities, they differ in chemical modifications and pharmacokinetic behavior, which has led to frequent confusion in the scientific literature.

Structural modification and albumin binding (preclinical)

A specific formulation of CJC-1295 incorporates a Drug Affinity Complex (DAC) through a lysine-based linker, enabling reversible binding to serum albumin. This structural feature has been investigated in preclinical studies for its ability to protect the peptide from rapid degradation and to extend its circulating persistence compared with non-DAC GHRH analogues.

For clarity in research contexts, the peptide containing this modification is commonly referred to as CJC-1295-DAC, while the non-modified form is referred to as CJC-1295 (no DAC).

GHRH signaling and hormonal axis research (preclinical)

In in vitro systems and animal studies, both CJC-1295-DAC and modified GRF (1-29) have been used to investigate GHRH-mediated signaling pathways involved in the regulation of growth hormone (GH) release. Experimental findings indicate that these peptides elicit qualitatively similar GH-related signaling patterns, while differing in the duration and temporal profile of their activity.

Modified GRF (1-29) has been characterized by a shorter signaling window, whereas CJC-1295-DAC exhibits a prolonged activity profile due to albumin association. These differences are exploited in laboratory settings to study pulse dynamics versus sustained stimulation of the GH–IGF axis.

IGF-related and metabolic pathway investigations (preclinical)

Preclinical research has explored the effects of CJC-1295-DAC on GH- and IGF-associated biochemical markers, including downstream pathways related to protein synthesis, lipid metabolism, glucose regulation, bone biology, and myocardial cellular signaling. These observations are used to map physiological response networks regulated by GHRH analogues under controlled experimental conditions.

Combination peptide research (preclinical)

CJC-1295-DAC has also been included in preclinical combination studies with growth hormone–releasing peptides (GHRPs) to examine synergistic or additive effects on GH-related signaling without altering unrelated hormonal pathways. These studies focus on mechanistic interactions within the endocrine signaling network, rather than functional or clinical outcomes.

Reproductive and developmental biology research (preclinical)

Earlier experimental investigations have examined GHRH analogues, including CJC-1295, in reproductive biology research contexts, exploring how GH- and IGF-associated signaling intersects with ovulatory and spermatogenic regulatory pathways in animal systems. These studies aim to clarify endocrine coordination mechanisms during reproductive cycles under experimental conditions.

REFERENCES

All information presented above is derived from in vitro experiments, animal studies, and other preclinical research models. These data are intended solely for basic scientific investigation of biological mechanisms and do not imply any therapeutic, diagnostic, preventive, or clinical use in humans or animals.     

M. Alba et al., "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse" [PubMed]

M. Alba et al., "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse" [American Journal of Physiology-Endocrinology and Metabolism]

S.L. Teichman et al., "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults" [PubMed]

L. Sackmann-Sala et al., "Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects" [PubMed]

A. Volpe et al., "Clinical use of growth hormone-releasing factor for induction of superovulation" [PubMed]

M. Ionescu et al., "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog" [PubMed]

DISCLAIMER

This product is intendend for lab research and development use only. These studies are performed outside of the body. This product is not medicines or drugs and has not been approved by the FDA or EMA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals.

All product information provided on this website is for informational and educational purposes only.